Abstract:A(3) adenosine receptor antagonists have potential as anti-inflammatory, anti-asthmatic, and anti-ischemic agents. We previously reported the preparation of chemical libraries of 1, 1-dihydropyridine (DHP) and pyridine derivatives and identification of members having high affinity at A(3) adenosine receptors. These derivatives were synthesized through standard three-component condensation/oxidation reactions, which permitted versatile ring substitution at five positions, i.e., the central ring served as a molecular scaffold for structurally diverse substituents. We extended this template approach from the DHP series to chemically stable pyran derivatives, in which the ring NH is replaced by O and which is similarly derived from a stepwise reaction of three components. Since the orientation of substituent groups may be conformationally similar to the 1,4-DH Ps, a direct comparison between the structure activity relationships of key derivatives in binding to adenosine receptors was carried out. Affinity at human Ag receptors expressed in CHO cells was determined vs, binding of [I-125]AB-MECA (N-6-(4-amino-3-iodobenzyl)-5'-N-methyl-carbamoyladenosine). There was no potency-enhancing effect, as was observed for DHPs, of 4-styryl, 4-phenylethynyl, or 6-phenyl substitutions. The most potent ligands in this group in binding to human A(3) receptors were 6-methyl and 6-phenyl analogs, 3a (MRS 1704) and 4a (MRS 1705), respectively, of 3,5-diethyl 2-methyl-4-phenyl-4H-pyran-3,5-dicarboxy which had K-i values of 381 and 583 nM, respectively. These two derivatives were selective for human A3 receptors vs. rat brain A(1) receptors by 57-fold and 24-fold, respectively. These derivatives were inactive in binding at rat brain A(2A) receptors, and at recombinant human A(2B) receptors displayed K-i values of 17.3 and 23.2 mu M, respectively. The selectivity, but not affinity of the pyran derivatives in binding to the A(3) receptor subtype was generally enhanced vs. the corresponding DHP derivatives. Drug Dev. Res. 48:171-177, 1999. Published 1999 Wiley-Liss, Inc.(+)

2,6-Diaryl-4-phenacylaminopyrimidines As Potent and Selective Adenosine A(2A) Antagonists with Reduced Herg Liability.

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides As A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy.

Synthesis of N-pyrimidinyl-2-phenoxyacetamides As Adenosine A2A Receptor Antagonists

2,6-Diaryl-4-acylaminopyrimidines As Potent and Selective Adenosine A2A Antagonists with Improved Solubility and Metabolic Stability

Identification of Novel, Water-Soluble, 2-Amino-n-pyrimidin-4-yl Acetamides As A2A Receptor Antagonists with in Vivo Efficacy

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.

2-Amino-<i>N</i>-pyrimidin-4-ylacetamides as A<sub>2A</sub>Receptor Antagonists: 2. Reduction of hERG Activity, Observed Species Selectivity, and Structure−Activity Relationships

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

2-Amino-<i>N</i>-pyrimidin-4-ylacetamides as A<sub>2A</sub>Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines As A(2a) Adenosine Receptor Antagonists for the Treatment of Parkinson'S Disease

Synthesis of Alkyne Derivatives of a Novel Triazolopyrazine As A2A Adenosine Receptor Antagonists.

Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Pyran Template Approach to the Design of Novel A3 Adenosine Receptor Antagonists

Selective A(3) Adenosine Receptor Antagonists: Water-Soluble 3, 5-Diacyl-1,2,4-trialkylpyridinium Salts and Their Oxidative Generation from Dihydropyridine Precursors.

2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor